Equillium, Inc.
2223 Avenida De La Playa
Suite 105
La Jolla, CA 92037
United States
858 240 1200
https://www.equilliumbio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 44
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Daniel Mark Bradbury | Executive Chairman | 158k | 無 | 1961 |
| Mr. Bruce D. Steel C.F.A. | Co-Founder, President, CEO & Director | 779.87k | 無 | 1966 |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Senior VP & COO | 553.73k | 無 | 1970 |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & Director | 571.32k | 無 | 1982 |
| Mr. Jason A. Keyes | Chief Financial Officer | 無 | 無 | 1971 |
| Penny Tom | Senior VP of Finance & Principal Accounting Officer | 無 | 無 | 無 |
| Mr. Michael Moore | Vice President of Investor Relations & Corporate Communications | 無 | 無 | 無 |
| Dr. Matthew Ritter Ph.D. | Senior Vice President of Corporate Development | 無 | 無 | 無 |
| Mr. Joel M. Rothman | Chief Development Officer | 無 | 無 | 1969 |
| Dr. Maple Fung M.D. | Chief Medical Officer | 無 | 無 | 無 |
描述
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
公司管治
截至 無 止，Equillium, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
